Showing results (41-50 of 181) with videos related to

Sort By:
Pageof 19
Annals of Hematology|September 6, 2015
Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥ 65 years with immune thrombocytopeniaMarc Michel, Jeffrey Wasser, Bertrand Godeau, et al.
American Journal of Hematology|September 30, 2011
Characteristics and outcome of immune thrombocytopenia in elderly: results from a single center case-controlled studyMarc Michel, Odile Beyne Rauzy, Francoise Roudot Thoraval, et al.
British Journal of Haematology|November 6, 2015
Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 studyAdrian Newland, Bertrand Godeau, Victor Priego, et al.
Internal Medicine Journal|March 1, 2019
Characteristics, risk factors and management of venous thromboembolism in immune thrombocytopenia: a retrospective multicentre studyGuillaume Le Guenno, Romain Guieze, Sylvain Audia, et al.
American Journal of Hematology|January 7, 2009
Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 casesGuillaume Bussone, Emmanuel Ribeiro, Agnès Dechartres, et al.
American Journal of Blood Research|February 17, 2017
Efficacy and safety of ClairYg®, a ready-to-use intravenous immunoglobulin, in adult patients with primary immune thrombocytopeniaBorhane Slama, Olivier Fain, Hervé Maisonneuve, et al.
American Journal of Blood Research|July 11, 2017
Erratum: Efficacy and safety of ClairYg®, a ready-to-use intravenous immunoglobulin, in adult patients with primary immune thrombocytopeniaBorhane Slama, Olivier Fain, Hervé Maisonneuve, et al.
International Journal of Hematology|July 24, 2015
Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostimDouglas B Cines, Terry Gernsheimer, Jeffrey Wasser, et al.
British Journal of Haematology|October 10, 2024
When is the use of intravenous immunoglobulin appropriate in immune thrombocytopenia?Sydney Dubois, Richard Layese, Nicolas Limal, et al.
Blood Advances|October 7, 2024
Sustained remission at long term follow-up in adolescents and young adults with chronic primary immune thrombocytopeniaAlexandra Schifferli, Gautier Le Gavrian, Nathalie Aladjidi, et al.
Pageof 19